One-year interim data from a Phase II study of Newron Pharmaceuticals’ schizophrenia candidate evenamide showed sustained efficacy and continued improvements in symptoms of psychosis and disease severity, the Milan-based company reported Thursday.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2025,